Company intelligence / Profile preview
Omikron Italia
- Ownership
- Private
- Development stage
- Commercial
Overview
Omikron Italia develops and markets pharmaceutical products and innovative therapeutic responses dedicated primarily to patients with major ophthalmic conditions and vascular diseases. The company positions itself as a partner for specialists and general practitioners in these fields. Product details are restricted to registered medical professionals.
- Therapeutic areas
- OphthalmologyCardiovascular
- Modalities
- small moleculesnutraceuticals/food supplements
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Omikron Italia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Omikron Italia.